Sunland Capital

Sunland Capital is a private equity firm specializing in acquisitions and buyouts in the lower middle-market. It seeks to buy, build, and hold the portfolio companies. The firm prefers to invest in service-oriented companies with a focus on niche energy service, industrial service, and infrastructure service. It targets companies situated in Southern United States, mid-continent, and Rockies Mountain area. The firm seeks to invest in companies with revenues between $5 million and $20 million and EBITDA between $1 million and $5 million. It prefers to have 100 percent ownership of the portfolio companies. It prefers to take a board seat. The firm also seeks add-on acquisition opportunities. Sunland Capital was founded in 2009 and is based in Houston, Texas with an additional office in Eunice, Louisiana.

Eddie J Soileau

Co-Founder & Chairman

Adam C Zylman

Co-Founder & CEO

4 past transactions

KYinno

Series A in 2021
Kyinno Biotechnology Co., Ltd. develops anti-tumor drugs and offers customized product development for immuno-oncology and kinase inhibitor discovery. It offers engineered cell lines and antibody products. The company offers services platforms, such as engineered custom cell line development, cell-based assay validation and compound screening, phage display library and hybridoma technology for antibody drug discovery, and cancer cell panel compound profiling and biomarker discovery. Kyinno Biotechnology Co., Ltd. was founded in 2017 and is based in Beijing, China.

Longhui Medical

Series B in 2021
Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service.

WuXi Diagnostics

Series B in 2021
WuXi Diagnostics is a provider of clinical diagnostic services that focuses on bridging the gap between research and clinical practice. The company offers a range of testing solutions, including screening and early diagnosis, clinical decision support, and prognosis management. By leveraging innovative models, WuXi Diagnostics aims to enhance diagnostic product innovation and generate valuable clinical insights. This approach is designed to improve health outcomes through precision diagnosis and treatment, ultimately benefiting patients and the broader healthcare community.